A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism

NCT ID: NCT05712421

Last Updated: 2025-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

303 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-28

Study Completion Date

2025-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The North Star study is a multi-center, Phase 2, double-blind, randomized, parallel group clinical study to evaluate the safe and effective dose conversion from Levothyroxine to North Star therapy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypothyroidism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

North Star

Group Type EXPERIMENTAL

North Star

Intervention Type DRUG

North Star

Levothyroxine

Group Type ACTIVE_COMPARATOR

Levothyroxine

Intervention Type DRUG

Levothyroxine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

North Star

North Star

Intervention Type DRUG

Levothyroxine

Levothyroxine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with primary hypothyroidism
* On continuous thyroid replacement therapy for at least 6 months before Study Entry
* On a stable daily dose of LT4 for a minimum of 12 weeks prior to Screening
* Agree to practice a method of contraception
* Female patients not pregnant or lactating at Screening
* Agree to practice a method of contraception of greater than 90% reliability
* Willing to give written informed consent for the Study
* Provide written authorization for use and disclosure of protected health information

Exclusion Criteria

* Any clinical condition or previous surgery that might affect the absorption, distribution, biotransformation or excretion of North Star or levothyroxine
* Hospitalization for a major illness within 4 weeks prior to Screening
* Anticipated initiation or change in concomitant medications
* Concomitant use of prohibited medications or supplements
* Participated in another investigational new drug study within 30 days or 5 half-lives of the IMP, whichever is longer, prior to the first study drug administration.
* For female subjects, be pregnant, nursing or planning to become pregnant during the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Neuvosyn Laboratories, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Neuvosyn Investigational Site

Birmingham, Alabama, United States

Site Status

Neuvosyn Investigational Site

Canoga Park, California, United States

Site Status

Neuvosyn Investigational Site

Greenbrae, California, United States

Site Status

Neuvosyn Investigational Site

Toluca Lake, California, United States

Site Status

Neuvosyn Investigational Site

Farmington, Connecticut, United States

Site Status

Neuvosyn Investigational Site

Boca Raton, Florida, United States

Site Status

Neuvosyn Investigational Site

Miami, Florida, United States

Site Status

Neuvosyn Investigational Site

Miami, Florida, United States

Site Status

Neuvosyn Investigational Site

Miami, Florida, United States

Site Status

Neuvosyn Investigational Site

Miami, Florida, United States

Site Status

Neuvosyn Investigational Site

Miami, Florida, United States

Site Status

Neuvosyn Investigational Site

Sunrise, Florida, United States

Site Status

Neuvosyn Investigational Site

Acworth, Georgia, United States

Site Status

Neuvosyn Investigational Site

Atlanta, Georgia, United States

Site Status

Neuvosyn Investigational Site

Columbus, Georgia, United States

Site Status

Neuvosyn Investigational Site

Sugar Hill, Georgia, United States

Site Status

Neuvosyn Investigational Site

Saginaw, Michigan, United States

Site Status

Neuvosyn Investigational Site

Gladstone, Missouri, United States

Site Status

Neuvosyn Investigational Site

Williamsville, New York, United States

Site Status

Neuvosyn Investigational Site

Denver, North Carolina, United States

Site Status

Neuvosyn Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Neuvosyn Investigational Site

Beavercreek, Ohio, United States

Site Status

Neuvosyn Investigational Site

Columbus, Ohio, United States

Site Status

Neuvosyn Investigational Site

Georgetown, Texas, United States

Site Status

Neuvosyn Investigational Site

Houston, Texas, United States

Site Status

Neuvosyn Investigational Site

Katy, Texas, United States

Site Status

Neuvosyn Investigational Site

Katy, Texas, United States

Site Status

Neuvosyn Investigational Site

Lewisville, Texas, United States

Site Status

Neuvosyn Investigational Site

Paris, Texas, United States

Site Status

Neuvosyn Investigational Site

Pearland, Texas, United States

Site Status

Neuvosyn Investigational Site

Stafford, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NorthStar-02-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thyroid Hormone for Thyroid Cancer
NCT06647602 NOT_YET_RECRUITING